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OBJECTIVES: Epilepsy is common chronic disorder characterized by recurrent 
unprovoked seizures with incidence rate of 20 to 70 per 100 000 population per 
year. Approximately 150,000 children sustain a first-time unprovoked seizure every 
year, and of those, 30,000 develop epilepsy. To evaluate the economic burden of pedi-
atric epileptic patients and cost of their epilepsy management from the patients’ 
perspective. METHODS: This study adopted a prospective cross sectional design by 
interviewing the patient’s parents from neurology clinic of Hospital Pulau Pinang, 
Malaysia. A retrospective data (for the past 12 months) was collected from patient’s 
medical record for the laboratory test, investigations and treatment received. The 
collected data included information about the patient’s resources utilization, lost 
productivity, and out of pocket expenditure. RESULTS: Majority of respondent was 
male which comprise of 64.2% whereby female was 35.8%. Mean (±SD) total annual 
cost from patient perspective was RM 1303.05 ± 2288.66 (USD 366.69±644.06) per 
patient. The highest item cost which contributes to the total annual cost was the 
loss of productivity which is RM 528.26 ± 786.22 (USD 148.66±221.25) followed by cost 
of caretaker RM 690.32 ± 1929.41 (USD 194.26±542.96) and meal/snack cost during 
clinic visit RM 44.97±56.87 (USD 12.66±16). The lowest contributor for annual cost 
from patient perspective was transportation cost with a mean of RM 39.51 ± 31.73 
(USD 11.22±8.93). CONCLUSIONS: In conclusion, from patients’ perspectives loss of 
productivity is the major contributor in economic burden to epilepsy management 
in pediatric. Type of seizure associated with neurological deficit and the response 
to the medication which affects the number of clinic visit, number of hospitaliza-
tion and length of hospital admission influence lifetime cost of epilepsy bear by 
the patient depending on employment and monthly incomes as well as who is the 
caretaker and who bring the child to clinic visit and accompanied the child during 
hospital admission.
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OBJECTIVES: No recent study on the medical costs of multiple-sclerosis (MS) 
has employed real world data to analyze relapsing-remitting multiple sclerosis 
(RRMS) and primary progressive multiple sclerosis (PPMS). This paper analyzes 
the medical costs of RRMS to identify the causes of the high medical costs of 
MS. METHODS: We selected subjects from among active employees and their fam-
ilies who were covered by private health insurance from MedStat Commercial Data 
from 2005 to 2012. We developed logic to identify MS patients, MS relapses and 
RRMS patients and PPMS patients with claims data. The PPPM of RRMS patients 
was analyzed in cases where relapsing intervals were greater than the average 
interval length. RESULTS: The PPPM of RRMS patients was $4,964 PPPM. The fre-
quency of RRMS relapses was 3.2 times during 5 years. The PPPM of RRMS patients 
was reduced by $958 PPPM when relapsing intervals were increased by 1.2 times 
compared to the usual RRMS relapsing intervals. The PPPM of RRMS patients was 
reduced by $1,139 PPPM when relapsing intervals were increased by 1.5 times 
compared to the usual RRMS relapsing intervals. CONCLUSIONS: The number 
of RRMS patients among MS patients was 87 %. The PPPM of relapses accounted 
for 83% of PPPM of RRMS. By restricting the frequency of relapses it is possible to 
reduce the PPPM of RRMS patients.
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OBJECTIVES: To evaluate the health care resource utilization and costs 
among patients diagnosed with chronic migraine (CM) in the Veterans Health 
Administration (VHA) medical dataset. METHODS: Patients diagnosed with CM 
were identified (International Classification of Diseases, 9th Revision, Clinical 
Modification diagnosis code 346.XX) using the VHA dataset from October 1, 2008 
through September 30, 2010. The initial diagnosis date was designated as the index 
date. Patients without CM with the same age, gender and region (comparison cohort) 
were matched using a randomly chosen index date to minimize selection bias. 
Patients in both cohorts were at least age 18 years and had continuous medical 
and pharmacy benefits for 1 year before and after the index date. One-to-one pro-
pensity score matching (PSM) was used to compare health care costs and utiliza-
tions between the CM and the comparison cohorts, and was adjusted for baseline 
demographic and clinical characteristics. Pain scores were also included to investi-
gate wellness after CM diagnosis. RESULTS: After risk-adjustment by PSM, 123,241 
patients in each cohort were matched. Significantly more CM patients had inpatient 
admissions (6.44% vs. 1.75%, p< 0.0001) and emergency room (ER; 14.42% vs. 5.50%, 
p< 0.0001), outpatient office (68.80% vs. 42.15%, p< 0.0001), outpatient (69.30% vs. 
42.91%, p< 0.0001) and pharmacy visits (70.84% vs. 41.43%, p< 0.0001) compared to 
those without CM. Accordingly, CM patients also incurred higher costs for inpa-
tient admissions and ER, office, outpatient and pharmacy visits compared to those 
without CM. Total costs incurred by CM patients were $4,776, almost triple that of 
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OBJECTIVES: To assess the trends in average wholesaler prices at market entry for 
multiple sclerosis (MS) disease-modifying therapies (DMTs) approved by the US 
Food and Drug Administration (FDA) in the period 1987-2014. METHODS: DMTs 
regulatory information was derived from the FDA website. Average wholesaler 
prices (AWP) per unit at market entry data were derived from the RedBook (Truven 
Health Analytics, Inc.). The AWP history was collected from year of approval to 
October 2014. The daily defined dosage (DDD) for adult patients was obtained 
from FDA approved labels. AWP per DDD and the AWP per year were computed. 
Descriptive statistics and Wilcoxon tests were performed. Statistical significance 
level was set at 0.05. RESULTS: The National Multiple Sclerosis Society listed 11 
FDA approved DMTs (5 new drug applications [NDA] and 6 biological license appli-
cations [BLA]) as of October 2014. Two products were approved by the FDA using 
priority review. The FDA granted orphan designation to 5 DMTs. Only one DMT 
had generic competition in the study period. There was one DMT approved by US 
FDA in the 1980s, three in the 1990s and 2000s, respectively, and 4 in the period 
2010-2014. The median AWP per DDD was $5.88 in the 1980s, $7.13 in the 1990s, 
$217.52 in the 2000s, and $274.76 in the period 2010–Oct 2014. Statistically signifi-
cant differences were found in median AWP per DDD prices between NDAs and 
BLAs. The median AWP per DDD was not significantly different for FDA priority 
review drugs compared to standard review drugs, and for orphan compared to 
non-orphan drugs. CONCLUSIONS: The median AWP per DDD for DMTs at market 
entry increased substantially over time. No statistically significant differences 
were found in the median AWP per DDD between priority and standard review 
drugs, and between orphan and non-orphan drugs.
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OBJECTIVES: To evaluate the economic consequences of having spinal muscular 
atrophy (SMA). METHODS: This study was conducted using Department of Defense 
Military Healthcare System (MHS) data from 2003 to 2012. Eligible persons had a 
SMA diagnosis (ICD-9CM codes 335.0 or 335.1) on 1 inpatient or 3 outpatient claims 
before 18 years of age. Individuals had at least 6 months of data after first SMA 
diagnosis; or died within 6 months after first SMA diagnosis; or had at least 12 
months of data before first SMA diagnosis. Subgroup analyses were conducted for 
early (≤1 years) and late diagnosis (>1 years). RESULTS: A total of 239 individu-
als met the inclusion criteria. The median total expenditure, while enrolled in the 
MHS, was $83,652 (25-75 percentile $29,620-$228,754) over a mean observation of 
6.9±3.6 years, though rare outlier costs were as high as $4.4 million. The mean age 
(SD) at first observed SMA diagnosis was 7.5±6.4 years. The mean (SD) duration of 
observation following initial SMA diagnosis was 4.8±3.3 years with a median cost 
of $60,213 ($18,229-$192,559). For all patients, the primary cost driver was outpa-
tient costs (median $53,152 ($23,902-$136,150)), followed by inpatient costs (median 
$11,258 ($0-$51,987)) and total prescription costs (median $3,167 ($943-$13,283)). 
The subgroup of patients with early diagnosis (n=45) had 4.3±2.9 years of observa-
tion with a median cost of $167,921 ($53,349-$678,412)). Approximately 17.8% of 
this subgroup died during the observation period, which highlights the devastating 
nature of early onset SMA. Patients with late diagnosis (n=194) had 7.5±3.4 years 
observation and median total costs of $70,380 ($28,196-$184,272). CONCLUSIONS: 
Individuals with SMA have a high degree of morbidity and mortality, particularly 
those diagnosed during infancy. SMA patients have significant medical expenditures 
and high utilization of health care services. There is significant economic burden 
caring for patients diagnosed with SMA. DISCLAIMER: Research derived from an IRB 
approved protocol at Naval Medical Center Portsmouth, VA. The views expressed in 
this abstract are those of the authors and do not necessarily reflect the official policy 
or position of the Department of the Army, Department of the Navy, Department of 
Defense or the United States Government. George J. Dahl and Rees Lee are members 
of the U.S. military. This work was prepared as part of their official duties. Title 17 
U.S.C. 105 provides that ‘Copyright protection under this title is not available for any 
work of the United States Government.’ Title 17 U.S.C. 101 defines a United States 
Government work as a work prepared by a military service member or employee of 
the United States Government as part of that person’s official duties.
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